Purpose Some macrolide and quinolone antibiotics (MQABs) are associated with QT prolongation and lifethreatening torsade de pointes (TdP) arrhythmia. MQAB may also inhibit cytochrome P450 isoenzymes and thereby cause pharmacokinetic drug interactions (DDIs). There is limited data on the frequency and management of such risks in clinical practice. We aimed to quantify co-administration of MQAB with interacting drugs and associated adverse drug reactions. Methods We conducted an observational study within our pharmacoepidemiological database derived from electronic medical records of a tertiary care hospital. Among all users of MQAB associated with TdP, we determined the prevalence of additional QT-prolonging drugs and risk factors and identified contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine. Electrocardiographic (ECG) monitoring and associated adverse events were validated in medical records. Results Among 3444 administered courses of clarithromycin, erythromycin, azithromycin, ciprofloxacin, levofloxacin, or moxifloxacin, there were 1332 (38.7 %) with concomitant use of additional QT-prolonging drugs. Among those, we identified seven cases of drug-related QT prolongation, but 49.1 % had no ECG monitoring. Of all MQAB users, 547 (15.9 %) had hypokalemia. Forty-four MQAB users had contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine and three of those related adverse drug reactions. Conclusion In the studied real-life setting, we found a considerable number of MQAB users with additional risk factors for TdP but no ECG monitoring. However, adverse drug reactions were rarely found, and costs vs. benefits of ECG monitoring have to be weighted. In contrast, avoidable risk factors and selected contraindicated pharmacokinetic interactions are clear targets for implementation as automated alerts in electronic prescribing systems.
Introduction
Macrolide and quinolone antibiotics (MQABs) are among the most frequently prescribed drugs that are associated with lifethreatening torsade de pointes (TdP) cardiac arrhythmia [1] [2] [3] [4] [5] . Information on the assessment of their potential risk to cause TdP vs. therapeutic benefits are featured in their summary of product characteristics (SPC) and other resources such as guidelines, websites, and clinical decision support software [6, 7] . Patients' resilience to drug-induced TdP is often Electronic supplementary material The online version of this article (doi:10.1007/s00228-016-2043-z) contains supplementary material, which is available to authorized users. described as Brepolarization reserve,^referring to the ventricle's capacity to compensate delayed repolarization [8] . Prolongation of the QT interval is an important predictor of TdP, and electrocardiographic (ECG) monitoring is therefore indicated in patients exposed to QT-prolonging drugs with a high risk of TdP. The risk is partially dose-dependent and highest in patients with concomitant administration of several QT-prolonging drugs. Indeed, in clinical practice, patients with drug-associated TdP had typically been exposed to several risk drugs. TdP is also associated with additional factors including high age, female sex, hypokalemia, heart diseases, and renal impairment [9] [10] [11] . If the QTc interval exceeds 500 ms or there is a drug-associated increase by more than 60 ms, QT-prolonging drugs should usually be discontinued [12] . However, the risk of TdP may already be increased at QTc intervals above the upper limit of normal, which is commonly defined as 450 ms for men and 460 ms for women [13] . Inpatients of a tertiary care hospital may frequently feature reduced repolarization reserves due to polypharmacy and other risk factors for TdP. Therefore, awareness of TdP-inducing drugs and careful ECG monitoring are important parts of proactive drug safety management in this population [14] .
Furthermore, some MQABs are also well known for avoidable pharmacokinetic drug-drug interactions (DDIs) [15, 16] . Clarithromycin, erythromycin, and ciprofloxacin are strong inhibitors of cytochrome P450 isoenzymes (CYPs). Their co-administration with certain substrates may outweigh any potential benefits, especially if Bvictim drugs^are prescribed in high doses and if therapeutic alternatives are available. The latency time of resulting adverse drug reactions (ADRs) has a broad range. DDI with MQAB may lead to simvastatininduced rhabdomyolysis only after several weeks of coadministration [17] [18] [19] , whereas ciprofloxacin may cause a sevenfold to tenfold increase of tizanidine c max and AUC within 24 h and result in severe hypotension and reduced psychomotor functions [20] .
The present study aimed to quantify co-administration of MQAB with QT-prolonging and other potentially interacting drugs, relevant risk factors, and the frequency of associated adverse drug reactions in the real-life setting of hospitalized patients.
Methods

Data source
The study was conducted using data from the calendar year 2012 of our previously described comprehensive pharmacoepidemiological hospital database [21] . The database contains information on electronic drug prescriptions, demographics, laboratory results, and diagnoses for hospitalized patients of a Swiss tertiary care hospital.
For the assessment of ECG monitoring and outcome validation of potential DDI, we reviewed original electronic medical records unless patients had refused consent to use their data for research upon admission.
Study design
Selection of the study population and overall study design are presented in Fig. 1 . We conducted a retrospective observational study that analyzed usage patterns, ECG monitoring, potential DDI, laboratory data, and relevant comorbidities in MQAB users of a tertiary care hospital. The cantonal ethics committee, the hospital's medical director, and the hospital's center for clinical research had approved the data extraction, the setup and analysis of our anonymized pharmacoepidemiological database, and the access to original medical records for our research studies.
Usage patterns of QT-prolonging MQAB, co-administration of potentially interacting drugs and risk factors for TdP
For the present study, we developed, programmed, and validated algorithms that searched our database for patients, patient-days, and hospitalizations with exposure to MQAB and co-administered drugs of interest. Few hospitalizations with administration of two or more of the studied MQAB contributed to more than one exposure group and were accordingly counted more than once. We analyzed the following MQAB based on their established high potential to cause TdP according to information from their SPC and additional scientific resources [7, [22] [23] [24] [25] : ciprofloxacin, clarithromycin, erythromycin, azithromycin, levofloxacin, and moxifloxacin. For all users of those MQABs, we identified additional co-administered drugs that also have an established high risk for QT prolongation and TdP. Furthermore, we identified selected drugs with well-documented relevant CYP-mediated pharmacokinetic interactions with the respective MQAB, i.e., concomitant administration of clarithromycin or erythromycin with simvastatin or high-dose atorvastatin (≥40 mg/day) and combined use of ciprofloxacin with tizanidine.
Further algorithms identified additional risk factors for TdP. Current hypokalemia below 3.3 mmol/l or renal impairment with a decreased eGFR [26] requires dose reduction for clarithromycin, erythromycin, ciprofloxacin, and levofloxacin. For patients with renal impairment, we evaluated whether recommended dose adjustments of the respective MQAB had actually been made [7] . Furthermore, we identified relevant cardiac comorbidities that may increase the risk of TdP based on documented International Classification of Diseases, Revision 10 (ICD-10) codes of the following heart diseases: heart failure, cardiomyopathy, angina pectoris, myocardial infarction, heart murmurs, aortic stenosis, coronary artery stenosis, cardiac failure, QT prolongation, pacemaker implantation, ventricular septum defect, coronary interventions, palpitations, atrial fibrillation or flutter, supraventricular arrhythmia, tachycardia, and tachy-bradycardia [3] .
ECG monitoring and evaluation of adverse events associated with potential medication errors
We assessed monitoring for QT prolongation by reviewing all documented ECGs in patients' original medical records performed up to 1 week before (baseline) or during the coadministration of potentially interacting drugs for each hospitalization.
A corrected QT interval (QTc) of >450 ms in men and >460 ms in women is associated with increased cardiovascular mortality and defined as the upper limit of normal by the American Heart Association. Longer QTc intervals were accordingly categorized as Babnormal QTc^for the present study [13, 27] . A QTc interval above 500 ms significantly increases the risk of TdP and sudden cardiac death and was defined as Blong QTc^ [12] . For patients with abnormal and long QTc intervals, we reviewed the original ECG and comprehensive medical records for other, not drug-related contributing QTc-prolonging factors such as pacemakers, left bundle branch blocks, or presence of tachycardia (heart rate > 100/min). Only if no such confounders were identified, we assessed the causal relationship with the respective QT-prolonging drugs according to standardized WHO/Council for International Organizations of Medical Sciences (CIOMS) causality assessment criteria [28] .
For the studied pharmacokinetic DDI involving simvastatin and atorvastatin, we identified symptoms, signs, and diagnoses of myopathy in comprehensive medical records including laboratory results of creatine kinase (CK) measurements [7] . For interactions involving tizanidine, we evaluated any Exclusion of 42 hospitalizations: -30 with non-drug causes -12 with ECG before exposure to DDI Fig. 1 Selection of the study population and overall study design documentation of hypotension, drowsiness, and reduced psychomotor functions [7] .
Data analysis
Data analysis was descriptive with presentation of results in tables as appropriate. Frequencies were calculated with regard to individual patients, hospitalizations, and patientdays. Data management and analyses were performed with STATA Version 13.1 (STATA Corporation, College Station, TX, USA).
Results
Characteristics of the study population Among 29,969 patients from our database that had been hospitalized in 2012, 9777 (32.6 %) had received treatment with systemic antibiotics. Amoxicillin-clavulanic acid was by far the most frequently used antibiotic (n = 4112, 42.1 %), and 29.1 % of patients with systemic antibiotic treatment had received MQAB associated with TdP. Characteristics of the studied MQAB users and frequency distribution of different MQAB are presented in Table 1 . Ciprofloxacin was the second most frequently used antibiotic in the hospital (19.2 % of all patients with systemic antibiotic treatment) and by far the most frequently used MQAB. Mean and median duration of hospitalization for MQAB users were 19.2 and 5 days.
Co-medication of MQAB with additional QT-prolonging drugs, other risk factors for TdP, and dose adjustment in renal impairment
Co-medication of MQAB with other QT-prolonging drugs and prevalence of additional risk factors for TdP are presented in Table 2 . Among 3444 courses of administered MQAB, additional drugs known to cause TdP were administered in 1332 (38.7 %). In 14.2 %, two or more additional QTprolonging drugs were administered. Some patients received up to six drugs known to cause TdP on the same day, frequently involving antiemetics, azole-antifungals, and antidepressants. Current hypokalemia below 3.3 mmol/l, an important risk factor for TdP, was documented in 15.9 %. For users of clarithromycin, erythromycin, ciprofloxacin, and levofloxacin, lack of recommended dose reduction of MQAB in the presence of renal impairment was found in 122 (3.8 %) of administered courses. Approximately one in three patients exposed to the studied MQAB had a documented ICD-10 diagnosis of heart diseases associated with an increased risk for TdP.
ECG monitoring in patients at risk for TdP
For 1332 administered MQAB courses with at least one additional QT-prolonging drug, medical records including performed ECGs could be further reviewed for 1236 (92.8 %).
Frequencies of ECG monitoring and further risk factors for TdP in those patients are presented in Table 3 . In 50.9 %, adequate ECG monitoring was documented. Among hospitalizations with adequate ECG monitoring and abnormal QTc (n = 55), patients with non-drug causes for ECG abnormalities (n = 30) or patients with an ECG performed before exposure to the DDI (n = 12) were excluded from the CIOMS causality assessment. Thereafter, 13 individual patients with an abnormal/long QTc interval remained for formal causality assessment. For seven patients with QTc between 478 and 518 ms, causality of the involved drugs known to prolong QT interval and cause TdP interval was classified as Bpossible,^and further details are presented in Table 4 . We identified no episodes of TdP.
Pharmacokinetic interactions of MQAB with simvastatin, atorvastatin, and tizanidine
Among the 546 individual patients taking clarithromycin or erythromycin, we detected nine patients with coadministration of simvastatin, six thereof taking 40-80 mg daily. An additional 22 patients were exposed to concomitant use of ≥40 mg atorvastatin daily. In none of these patients, symptoms or signs of myopathy including elevated creatine kinase measurements indicated causally related adverse drug reactions. Among the 2247 administered courses of ciprofloxacin, we detected 13 with concomitant exposure to tizanidine, 5 thereof with ≥6 mg/day. Three patients experienced episodes of hypotension shortly after this combination was administered, and two patients were treated with cardiac stimulants (etilefrine and midodrin) but without cessation of tizanidineciprofloxacin co-administration (Supplementary Table 3) . Causality for the decreases in blood pressure assessment in relation to the DDI was assessed as possible in all three cases.
Discussion
This study describes the use, co-medication, and risk management of MQAB in the real-life setting of a tertiary care hospital with regard to TdP and to selected clinically relevant pharmacokinetic DDI. With the exception of ciprofloxacin, the studied potentially QT-prolonging MQAB were only used in a small proportion of patients. And, ciprofloxacin is generally considered Bless torsadogenic^than other quinolones and was only recently added to the list of drugs with a known risk for TdP [2, 29, 30] . At the same time, it is remarkable how many MQAB users had additional risk factors for TdP. Most notably, more than one third was exposed to additional QTprolonging drugs, and about one in six MQAB users also For clarithromycin if GFR < 30 ml/min, for erythromycin if GFR < 10 ml/min, for ciprofloxacin GFR < 30-60 ml/min, for levofloxacin if GFR < 20-50 ml/min/l on day(s) of co-administration e Abnormal QTc = 450 ms for men/460 ms for women; long QTc ≥ 500 ms had hypokalemia, a risk factor that is usually easy to correct in hospitalized patients [12, 31] . Indeed, the SPC of clarithromycin features hypokalemia as an explicit contraindication to its use [7, 32 ], yet we detected 361 patient-days in which clarithromycin was administered despite current serum potassium below 3.3 mmol/l, representing 8.5 % of all patientdays with exposure to clarithromycin (Supplementary Table  2 ). Renal impairment is another important risk factor for TdP, which may be explained by the reduced renal elimination of many drugs known to cause TdP and an increased risk for electrolyte disturbances [12] . We identified lack of dose adjustment for renally eliminated MQAB. Although this concerned only a little less than 5 % of MQAB users, it represents a risk that can be avoided if physicians are aware of it. ECGs for the monitoring of abnormal or long QT intervals were available in about 50 % in MQAB users with additional QT-prolonging co-medication. The higher proportion of patients with diagnosed heart diseases among the patients with adequate ECG monitoring may most likely be explained by confounding from the cardiac disease itself rather than a higher awareness for the drug-induced risk of TdP. A high proportion of patients without adequate ECG monitoring had at least one additional risk factor for TdP, and it is likely that additional cases of abnormal/long ECG remained undetected. On the other hand, medical records were searched for adverse drug reactions also in patients without ECG monitoring, and overall, only seven cases of prolonged QTc between 478 and 518 ms were identified and no case of TdP. The resources required for more intense and guideline-compliant ECG monitoring must therefore be weighed against expected benefits. Some US tertiary care hospitals have successfully developed and introduced automated algorithms with subsequent alerts for ECGs with a QTc >500 ms [33] [34] [35] [36] . However, in order for such a system to be effective, a current plus a recent pre-treatment ECG are needed, and also pre-treatment ECGs must be justified [37, 38] . Our findings suggest that automated algorithms to improve the risk assessment may include the following modifiable risk factors: hypokalemia, lack of dose adaptation to renal insufficiency, and ideally also suggestions for alternative co-medication. Nevertheless, the development of cost-effective ECG monitoring algorithms and their implementation remains challenging, for MQAB users as well as for other high-risk groups such as users of psychiatric drugs [39] .
In comparison to QT-prolonging combinations, management implications of our findings regarding selected contraindicated combinations of MQAB with known pharmacokinetic interactions are straightforward. A higher proportion of patients with such combinations had associated adverse drug reactions, and review of individual situations in original medical record showed that these combinations could have been avoided, as there would have been alternative management options in all cases. Rather simple automated alert algorithms Cardiomyopathy could therefore be an efficient preventive measure with a favorable relation of costs vs. benefits.
In conclusion, our study found a considerable number of MQAB users with additional QT-prolonging co-medication and other risk factors for TdP in hospitalized patients, and a high proportion of those had no ECG monitoring. However, adverse drug reactions were rarely found, and benefits of intense ECG monitoring as well as benefits of QT-prolonging co-medication in MQAB users have to be weighed against costs. In contrast, correctable co-factors in MQAB users such as hypokalemia, lack of dose adjustment in renal impairment and selected contraindicated pharmacokinetic interactions are clear targets for implementation as preventive automated alerts in electronic prescribing systems.
